pocketful logo
Hikal Ltd logo

Hikal Ltd

NSE: HIKAL BSE: 524735

₹168.48

(1.53%)

Mon, 30 Mar 2026, 10:55 am

mtf coin illustrationMTF 5x

Company History

1988

  • The company was incorporated on 8th July with the objective of carrying on the business of manufacture and marketing of chemicals, intermediates, dyes, pharmaceuticals, and pesticides.
  • Hikal Chemical Industries Limited was jointly promoted by Surajmukhi Investment and Finance Limited and the Hiremath family.
  • The company set up manufacturing facilities at Mahad over land admeasuring 27004 square metres.

1990

  • HCIL became a deemed public company under the provisions of Section 43 A of the Companies Act, 1956.
  • The company obtained a fresh Certificate of Incorporation from the Registrar of Companies.
  • The company proposed to enter the business of agrochemicals and commence production of Metoxuron and Metamitron.

1991

  • The company issued 1,50,000 shares to Hiremath Chemicals Limited in lieu of technical know-how and engineering.
  • The company entered into a Memorandum of Understanding with Hiremath Chemicals Ltd. for transfer of technology and technical assistance.

1993

  • Sumitomo Corporation, Japan acquired an equity stake in the company.
  • Hikal was the first chemical company in India in which Sumitomo Corpn. took equity.
  • The company entered into an agreement with Mr. Jai. Hiremath on his appointment as the Managing Director.

1994

  • The company became a full-fledged Public Limited Company.
  • The company made a public issue of 7,50,000 equity shares.
  • The public issue received an overwhelming response from investors and was oversubscribed by 21.48 times.

1995

  • The company completed the expansion of the Meta Chloro Aniline and Para Cumidine Plants.
  • The company undertook diversification in the field of Agro Chemicals and started production of Metoxuron.
  • The company entered into a long-term exclusive contract with Searle (India) Ltd.
  • The company issued 593926 bonus shares.
  • The company issued 445722 equity shares and 22500 equity shares on rights and preferential basis respectively.
  • The company planned to introduce new products to improve profitability.

1996

  • The Metoxuron plant was successfully commissioned and commercial production commenced.
  • The company maintained the highest standards of safety and environment care.

1997

  • Hikal Chemicals Industries Limited was engaged in the production of chemicals used by the pharmaceuticals, agro chemicals, and dye industries.
  • The company launched Metoxuron, a technical wheat herbicide.
  • The company entered into an agreement with Searle India for the purchase of Metoxuron.
  • The company issued 4,00,000 14% Non Convertible Cumulative Redeemable Preference Shares.
  • The company allotted 14,66,700 equity shares to promoters and Sumitomo Corporation, Japan on Preferential allotment basis.

1998

  • The company appointed a representative in England to increase export.
  • The company entered into a 10-year agreement with Merck & Co. Inc., U.S.A. for exclusive supply of Thiabendazole.

1999

  • The promoters of Hikal Chemicals Industries Ltd made an unconditional cash open offer to all equity shareholders.
  • Hikal set up a plant with the technical support of Merck & Co Inc.
  • Hikal was in talks for joint ventures with pharmaceutical and agrochemical multinationals.
  • The company undertook several measures to improve the profitability of the Mahad unit and started manufacturing and exporting Isoproturon.
  • The Mahad unit received ISO 9000 certification.

2000

  • Hikal Chemical Industries Ltd. issued one bonus share for every one share held by its shareholders.
  • Hikal Chemical Industries Ltd. changed its name to Hikal Ltd.
  • Hikal Chemical Industries Ltd. was awarded the 'British Safety Council' award for world-class health, safety, and environmental standards at their Taloja plant near Mumbai.

2002

  • Hikal appointed Mr. Bimal Kishore Raizada as the Additional Director of the company.

2003

  • The Board approved the issue of Bonus shares.
  • Hikal signed an agreement with a US-based pharmaceutical company to supply Gabapentin.
  • Hikal entered into a Long-term supply agreement with a leading Corp protection company in USA for supply of new generation agrochemical.

2004

  • Hikal Limited informed that the Company had applied for delisting of its securities from Ahmedabad Stock Exchange and Pune Stock Exchange.
  • Hikal entered into a long-term agreement with Bayer CropScience AG.
  • Hikal acquired European Pharma Distributor Marsing & Co.
  • Hikal took over Danish company.

2005

  • Hikal Ltd entered into a long-term agreement with a leading American Company, Crompton Corporation, USA, for manufacture and supply of a New Generation crop protection product.
  • Hikal joined Pfizer's epilepsy drug marketing row in US.

2006

  • Hikal Ltd signed an agreement with Germany's third-largest chemical company Degussa for supplying pharmaceutical intermediates and active pharma ingredients (APIs).
  • The Registered Office of the Company was shifted from 6, Nawab Building, 327, Dr. D. N. Road, Fort, Mumbai-400 001 to 717/718 Maker Chamber V, 7th Floor, Nairman Point, Mumbai-400 021.

2011

  • The Board appointed Dr. Wolfgang Welter as an Additional Director.
  • The prestigious 'Hikal Cup' Corporate Tennis Tournament was played at the Bombay Gymkhana Tennis Courts.

2012

  • Hikal Board recommends Final Dividend on the Equity Share Capital at 60%.

2013

  • Hikal's Pharmaceutical Manufacturing Site in Gujarat, India received US FDA Approval.
  • Hikal Ltd Board recommends Dividend on Equity Share Capital at 25%.
  • Hikal signed a long-term supply agreement with a leading global Biopharmaceutical Company.

2014

  • Hikal Ltd Board recommends Dividend on Equity Share Capital at Rs. 4.5 per equity share.
  • Hikal completed a successful EDQM Audit of its Bangalore facility.

2015

  • Hikal split its face value from Rs. 10 to Rs. 2.

2017

  • Hikal won the most coveted ICC Award for Excellence in Human Resource Management in the Chemical Industry for the year 2016.

2018

  • The Global Employer Branding Institute and World HRD Congress conferred Hikal with the 'National Best Employer Brands 2018'.
  • The Company issued Bonus Shares in the Ratio of 1:2.

2019

  • Hikal was conferred with the CSR Leadership Award for Best Corporate Social Responsibility Practices by the World CSR Congress.
  • Hikal won the Confederation of Indian Industry (CII)'s 'Significant Achievement in HR Excellence' award at the CII National HR Excellence Award.

2021

  • Hikal signed a 10-year multi-product contract with a leading global pharmaceutical innovator company.

2024

  • The Company acquired a 5.73 percent stake in FPEL Ujwal Private Limited.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800